Results 161 to 170 of about 66,320 (342)
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
Scoping Review of the Socioeconomic Value of Working Equids, and the Impact of Educational Interventions Aimed at Improving Their Welfare. [PDF]
Cameron A +4 more
europepmc +1 more source
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto +13 more
wiley +1 more source
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra +10 more
wiley +1 more source
Enhancing Healthcare Access for Older Adults through Innovative Mobility Solutions Leveraging Public Assets. [PDF]
Yokota M, Nakahara S, Nishida M.
europepmc +1 more source
ROAD TRANSPORT OF GOODS IN INDONESIA: INFRASTRUCTURE, REGULATORY AND BRIBERY COSTS
Brasukra G. Sudjana
openalex +1 more source

